These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 26916733)

  • 1. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
    Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients.
    Kempen HJ; Gomaraschi M; Simonelli S; Calabresi L; Moerland M; Otvos J; Jeyarajah E; Kallend D; Wijngaard PLJ
    Atherosclerosis; 2016 Dec; 255():17-24. PubMed ID: 27816804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.
    Kallend DG; Reijers JA; Bellibas SE; Bobillier A; Kempen H; Burggraaf J; Moerland M; Wijngaard PL
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):23-9. PubMed ID: 27418968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size.
    Kempen HJ; Schranz DB; Asztalos BF; Otvos J; Jeyarajah E; Drazul-Schrader D; Collins HL; Adelman SJ; Wijngaard PL
    J Lipids; 2014; 2014():923903. PubMed ID: 25478232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers.
    Bisgaier CL; Ackermann R; Rea T; Rodrigueza WV; Hartman D
    Pharmacol Res; 2016 Sep; 111():86-99. PubMed ID: 27155060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
    Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
    Diditchenko S; Gille A; Pragst I; Stadler D; Waelchli M; Hamilton R; Leis A; Wright SD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2202-11. PubMed ID: 23868939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.
    Kempen HJ; Gomaraschi M; Bellibas SE; Plassmann S; Zerler B; Collins HL; Adelman SJ; Calabresi L; Wijngaard PL
    J Lipid Res; 2013 Sep; 54(9):2341-53. PubMed ID: 23828780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice.
    Bielicki JK; Forte TM; McCall MR; Stoltzfus LJ; Chiesa G; Sirtori CR; Franceschini G; Rubin EM
    J Lipid Res; 1997 Nov; 38(11):2314-21. PubMed ID: 9392429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.
    Asztalos BF; Horvath KV; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2007-2015. PubMed ID: 30002062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles.
    Sviridov D; Pyle L; Fidge N
    Biochemistry; 1996 Jan; 35(1):189-96. PubMed ID: 8555173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
    Gille A; Easton R; D'Andrea D; Wright SD; Shear CL
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2106-14. PubMed ID: 24969776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma.
    Miccoli R; Zhu Y; Daum U; Wessling J; Huang Y; Navalesi R; Assmann G; von Eckardstein A
    J Lipid Res; 1997 Jun; 38(6):1242-53. PubMed ID: 9215551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.
    Cukier AMO; Therond P; Didichenko SA; Guillas I; Chapman MJ; Wright SD; Kontush A
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):890-900. PubMed ID: 28529180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).
    Ibanez B; Giannarelli C; Cimmino G; Santos-Gallego CG; Alique M; Pinero A; Vilahur G; Fuster V; Badimon L; Badimon JJ
    Atherosclerosis; 2012 Jan; 220(1):72-7. PubMed ID: 22030095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
    Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
    Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis.
    Hafiane A; Genest J
    Atherosclerosis; 2017 Feb; 257():90-99. PubMed ID: 28129550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
    Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH
    J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL Improves Cholesterol and Glucose Homeostasis and Reduces Atherosclerosis in Diabetes-Associated Atherosclerosis.
    Di Bartolo BA; Cartland SP; Genner S; Manuneedhi Cholan P; Vellozzi M; Rye KA; Kavurma MM
    J Diabetes Res; 2021; 2021():6668506. PubMed ID: 34095317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus.
    Tan HC; Tai ES; Sviridov D; Nestel PJ; Ng C; Chan E; Teo Y; Wai DC
    J Clin Lipidol; 2011; 5(6):467-73. PubMed ID: 22108150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.